Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Marcus E. Randall; Virginia L. Filiaci; D. Scott McMeekin; Vivian von Gruenigen; Helen Huang; Catheryn M. Yashar; Robert S. Mannel; Jae‐Weon Kim; Ritu Salani; Paul DiSilvestro; James J. Burke; Thomas Rutherford; Nick M. Spirtos; Keith Y. Terada; Penny R. Anderson; Wendy R. Brewster; William Small; Carol Aghajanian; David S. Miller

doi:10.1200/jco.18.01575

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Superiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Randall et al. (2019) studied this question.

synapsesocial.com/papers/69dcc406a5c75be4cfe53f7a https://doi.org/10.1200/jco.18.01575

View Full Paper

Ask AI

Bookmark

Share

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading